Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl

Apricus Biosciences, Inc. today announced that an additional analysis conducted on behalf of the Company has shown that MycoVa™ has successfully demonstrated 'non-inferiority' for the treatment of onychomycosis (commonly referred to as nail fungus), compared to the current standard of care in Europe for topical therapy, Loceryl®.

20 Jan 2011

USPTO grants KL4 surfactant combination product patent to Discovery Labs

Discovery Laboratories, Inc. has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 7,863,241 titled "Compositions for Treatment and Prevention of Pulmonary Conditions." The patent provides broad coverage for compositions that employ a combination of certain pulmonary surfactants with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

19 Jan 2011

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.

19 Jan 2011

Positive preliminary results from Soligenix's SGX202 in GARS model

Soligenix, Inc., a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 in a canine gastrointestinal acute radiation syndrome model.

19 Jan 2011

DKMA issues GMP certificate to Cambrex Zenara Indian manufacturing facility

Cambrex Corporation announced today that the Danish Medicines Agency (DKMA) has issued a Certificate of Good Manufacturing Practice (GMP) compliance for its manufacturing site in Hyderabad, India, following an audit conducted in October 2010. The DKMA Certificate is accepted by all EU Health Authorities and by authorities of several other countries that recognize EU Certification.

18 Jan 2011

Alexza completes FDA review for AZ-004 NDA

Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.

18 Jan 2011

PecFent accepted in Scotland for treatment of breakthrough cancer pain

Archimedes Pharma Ltd., a leading international specialty pharma company, today announced the decision by the Scottish Medicines Consortium to accept PecFent for use within NHS Scotland. PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

18 Jan 2011

New magnetic pill system can serve as drug delivery tool in patients with cancer, diabetes

A new magnetic pill system developed by Brown University researchers could solve the problem by safely holding a pill in place in the intestine wherever it needs to be.

18 Jan 2011

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

EffRx moves to Switzerland

Former EffRx, Inc., Jupiter, FL, USA is now EffRx Pharmaceuticals SA, Biopôle, Route de la Corniche 4, Epalinges/Lausanne, Switzerland. The move took place on September 18, 2010 through a share exchange agreement.

11 Jan 2011

Scientists create particles that resemble RBC, pave way for development of synthetic blood

A team of scientists has created particles that closely mirror some of the key properties of red blood cells, potentially helping pave the way for the development of synthetic blood.

11 Jan 2011

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.

11 Jan 2011

Enlight Biosciences forms new oral drug delivery technology company

Entrega, Inc., a new company developing oral drug delivery technologies, today announced its formation by Enlight Biosciences, a Boston-based company established in partnership with a group of leading global pharmaceutical companies.

10 Jan 2011

EffRx submits EX101 NDA for osteoporosis treatment to FDA

EffRx Pharmaceuticals SA, a Lausanne, Switzerland based drug delivery company announces the NDA submission of the company's lead project to the US Food and Drug Administration.

10 Jan 2011

Pennsaid fourth quarter prescriptions increase 20% sequentially

Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.

10 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., and RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

7 Jan 2011

Synageva BioPharma, to-BBB to evaluate brain drug delivery technology

Synageva BioPharma Corp. and to-BBB technologies BV, the Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system.

6 Jan 2011

FDA grants additional marketing exclusivity to INOMAX for pediatric BPD treatment

Ikaria, Inc. today announced that the U.S. Food and Drug Administration has granted INOMAX for inhalation an additional six months of marketing exclusivity, known as "pediatric exclusivity."

6 Jan 2011

Drug Delivery News and Research

Further Reading

Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl

USPTO grants KL4 surfactant combination product patent to Discovery Labs

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Positive preliminary results from Soligenix's SGX202 in GARS model

DKMA issues GMP certificate to Cambrex Zenara Indian manufacturing facility

Alexza completes FDA review for AZ-004 NDA

PecFent accepted in Scotland for treatment of breakthrough cancer pain

New magnetic pill system can serve as drug delivery tool in patients with cancer, diabetes

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

EffRx moves to Switzerland

Scientists create particles that resemble RBC, pave way for development of synthetic blood

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

Enlight Biosciences forms new oral drug delivery technology company

EffRx submits EX101 NDA for osteoporosis treatment to FDA

Pennsaid fourth quarter prescriptions increase 20% sequentially

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Synageva BioPharma, to-BBB to evaluate brain drug delivery technology

FDA grants additional marketing exclusivity to INOMAX for pediatric BPD treatment

Event guide: World ADC Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo